Agile Therapeutics's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Agile Therapeutics (NASDAQ:AGRX) is scheduled to release its quarterly earnings report on March 28, 2024, with analysts expecting an EPS of $-0.92. The company's past earnings performance shows a pattern of beating EPS estimates but experiencing subsequent share price drops. Over the last year, AGRX shares have declined by 96.87%, indicating a bearish outlook among long-term shareholders.
March 27, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Agile Therapeutics is expected to report an EPS of $-0.92 for the upcoming quarter. Historical data shows the company often beats EPS estimates but experiences share price declines following the announcements. With a 96.87% decrease in share price over the last year, investor sentiment appears bearish.
Given the historical pattern of EPS beats followed by share price declines and the significant annual decrease in share price, it's likely that AGRX's stock will face short-term downward pressure post-earnings announcement, despite potentially beating the EPS estimate.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100